New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For FLDM;LLY;OVSC;STEM;LH;PFE;NBS;ACTC;ATHX;PSTI;CYTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 20, 2014
07:12 EDTPFECongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
07:11 EDTPFEAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTPFE, FLDMAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 17, 2014
16:41 EDTPFEPfizer confirms FDA labeling approval for EMBEDA capsules
Pfizer announced that the FDA has approved an updated label for EMBEDA extended-release capsules, for oral use to include abuse-deterrence studies. The updated label states that EMBEDA has properties that are expected to reduce abuse via the oral and intranasal routes when crushed. However, abuse of EMBEDA by these routes is still possible. The updated label also includes data from a human abuse potential study of intravenous, or IV, morphine and naltrexone to simulate crushed EMBEDA. However, it is unknown whether the results with simulated crushed EMBEDA predict a reduction in abuse by the IV route until additional postmarketing data are available. EMBEDA is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Pfizer expects EMBEDA will be available in the U.S. in early 2015.
16:30 EDTPFEFDA approves new labeling from Embeda extended-release capsules
Subscribe for More Information
10:51 EDTLLYOptions with increasing implied volatility
Options with increasing implied volatility: COV DISH HLT QEP GREK BKW BYI LLY DTV TIBX
October 16, 2014
14:36 EDTLLYLilly to close Guayama facility, will take 16c charge in Q4
Eli Lilly announced plans to conclude production and pursue a sale of one of its three manufacturing plants in Puerto Rico. The manufacturing site, located in Guayama, Puerto Rico, will remain in operation until the end of 2015. All of the approximately 100 full-time non-contracted employees currently working in Guayama will be offered employment at Lilly's Carolina, Puerto Rico, location. As a result of this action, the company expects to record a charge of approximately $170M or approximately 16c per share, after tax, in Q414. While Lilly will initiate efforts to sell the Guayama site, the company will continue to invest in two manufacturing plants at Carolina. In November 2013, Lilly announced a $200M investment to increase capacity in its Carolina-based insulin active ingredient manufacturing plant. In July, Lilly announced an additional $40M in investments to increase capabilities at its Carolina-based drug product site as part of a rebalancing of Lilly's oral solid dosage network.
08:38 EDTPFEBaxter expects divestiture of vaccines business to Pfizer to close in Q4
Subscribe for More Information
08:08 EDTPFEActavis confirms generic Quillivant XR patent challenge
Subscribe for More Information
07:28 EDTPFEFDA to hold a joint advisory committee meeting on Chantix
Subscribe for More Information
October 15, 2014
19:16 EDTLHLabCorp acquisition of LipoScience clears antitrust approval
Laboratory Corporation of America Holdings, or LabCorp (LH), announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to the acquisition of LipoScience, Inc. (LPDX) by LabCorp. The transaction is expected to close in Q4.
16:11 EDTLHLabCorp's LipoScience acquisition clears antitrust approval
LipoScience (LPDX) announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to the acquisition of LipoScience by Laboratory Corporation of America Holdings (LH). The transaction remains subject to other customary closing conditions set forth in the Agreement and Plan of Merger, dated September 24. The transaction is expected to close in Q4.
15:00 EDTPFEShire-Allergan, AbbVie-Pfizer deals possible if merger scrapped, Bloomberg says
Subscribe for More Information
14:47 EDTCYTXSabby reports 9.99% passive stake in Cytori Therapeutics
Subscribe for More Information
October 14, 2014
18:39 EDTACTCAdvanced Cell Technology's RPE cells show positive Phase 1/2 results
Subscribe for More Information
16:42 EDTPSTIPluristem Therapeutics files $200M mixed securities shelf
11:23 EDTPFEBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
07:15 EDTLLYBiotech Industry Organization to hold a summit
Subscribe for More Information
06:05 EDTNBSBioLife Solutions biopreservation products used at Progenitor Cell Therapy
BioLife Solutions (BLFS) provided an update on use of the company's HypoThermosol storage/shipping media and CryoStor cryopreservation freeze media by Progenitor Cell Therapy, or PCT, a wholly owned subsidiary of NeoStem (NBS) a leader in the emerging cellular therapy field.
October 13, 2014
08:01 EDTPFEPfizer announces FDA acceptance of Palbociclib NDA with priority review
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use